Jay Gibbons
6 Papers
97 Citations
Jay Gibbons is an academic researcher. The author has contributed to research in topics: Neuroblastoma & ALK inhibitor. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.
Leora Horn,Jeffrey R. Infante,George R. Blumenschein,Heather A. Wakelee,Hendrik-Tobias Arkenau,Gary Dukart,Chris Liang,K. Harrow,Jay Gibbons,Christine M. Lovly,William Pao +10 more
TL;DR: X-396 is a novel, potent anaplastic lymphoma kinase (ALK) small molecule TKI with significant anti-tumor activity in both ALK TKI naive and crizotinib resistant models of ALK fusi...
45
Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment
Irina Lambertz,Candy Kumps,Shana Claeys,Sven Lindner,Anneleen Beckers,Els Janssens,Daniel R. Carter,Alex Cazes,Belamy B. Cheung,Marilena De Mariano,David Camacho-Trujillo,An De Bondt,Sara De Brouwer,Jay Gibbons,I. Janoueix-Lerosey,Genevieve Laureys,Chris Liang,Glenn M. Marshall,Michaël Porcu,Junko Takita,Ilse Van den Wyngaert,Nadine Van Roy,Alan Van Goethem,Tom Van Maerken,Piotr Zabrocki,Jan Cools,Johannes H. Schulte,Jorge Vialard,Franki Speleman,Katleen De Preter +29 more
- 01 Jan 2015
TL;DR: The negative feedback loop of MAPK pathway inhibitors may affect novel ALK inhibition therapies, whereas mutant ALK induced RET signaling can offer novel opportunities for testing ALK-RET oriented molecular combination therapies.
43
Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors.
Kathleen N. Moore,Suzanne F. Jones,Carla Kurkjian,Hendrik-Tobias Arkenau,Jeffrey R. Infante,Shubham Pant,Howard A. Burris,D. Scott McMeekin,Jay Gibbons,K. Harrow,Chris Liang,Sara Ramsey,Johanna C. Bendell +12 more
TL;DR: X-82 is a highly potent VEGFR/PDGFR TKI with a smaller volume of distribution and limited tissue accumulation designed to minimize side effects while maintaining target effect.
9
Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Leora Horn,Heather A. Wakelee,George R. Blumenschein,Karen L. Reckamp,S. Waqar,Corey A. Carter,Barbara J. Gitlitz,J. R. Infante,Rachel E. Sanborn,Joel W. Neal,J.P. Gockerman,Gary Dukart,K. Harrow,C. Liang,Jay Gibbons,Jennifer Hernandez,T. Newman-Eerkes,L. Lim,Christine M. Lovly +18 more
4